Jane Street’s Genmab GMAB Stock Holding History

Jane Street’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.52M	Buy	237,300 +132,200	+126%	+$3.51M	﹤0.01%	3346
2026 Q1	$2.82M	Buy	105,100 +65,700	+167%	+$1.97M	﹤0.01%	4461
2025 Q4	$1.21M	Buy	39,400 +22,900	+139%	+$714K	﹤0.01%	5755
2025 Q3	$506K	Buy	+16,500	New	+$402K	﹤0.01%	7835
2022 Q4	–	Sell	-42,900	Closed	-$1.38M	–	9479
2022 Q3	$1.38M	Buy	+42,900	New	+$1.51M	﹤0.01%	4848
2021 Q4	–	Sell	-90,300	Closed	-$3.95M	–	10341
2021 Q3	$3.95M	Buy	+90,300	New	+$4.05M	﹤0.01%	3135
2020 Q4	–	Sell	-11,500	Closed	-$416K	–	7706
2020 Q3	$416K	Buy	+11,500	New	+$416K	﹤0.01%	5438

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's GMAB Position: Q2 2026 in Review

Jane Street increased its Genmab (GMAB) stake by 67% in Q2 2026, buying an estimated $1.76M and bringing the position to 164,743 shares worth $4.53M. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

Jane Street first reported a position in GMAB in Q3 2019 and has held it in 16 quarters since. The position peaked at $7.73M in Q1 2023. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Jane Street held 164,743 shares of Genmab worth $4.53M as of Q2 2026.
Jane Street bought 66,311 Genmab shares in Q2 2026, an estimated $1.76M.
Genmab made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3847 holding.
Jane Street first reported a position in Genmab in Q3 2019 and has held it in 16 quarters since.
Jane Street's Genmab position peaked at $7.73M in Q1 2023.
292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.